Amarillo switching to Sotrovimab at COVID-19 Infusion Center

Due to new direction from the Centers for Disease Control and Prevention (CDC) and the Texas Department of State Health Services (TDSHS), the Amarillo Area Infusion Center will begin providing Sotrovimab for COVID-19 patients on Friday (Dec. 24.)

Sotrovimab will replace Bamlanivimab and Regeneron as treatment for COVID-19 patients eligible for treatment at the infusion center, located at 808 S. Johnson St. The infusion center uses a prioritization method for treatment for the most vulnerable patients as supplies remain limited.

The Amarillo Area Infusion Center does not provide COVID-19 vaccines – and this directive from the CDC and TDSHS has no impact on COVID-19 vaccine availability or efficacy. 

The CDC estimates that the Omicron COVID-19 variant is causing more than 90 percent of COVID-19 cases in Texas and surrounding states. Sotrovimab is deemed more effective against the Omicron variant. 

The infusion clinic is a preparatory initiative for outpatient treatments to a limited population of qualifying positive COVID-19 patients. The infusion clinic is supported by the State of Texas and the City of Amarillo.

Post a Comment

Previous Post Next Post